ConPharm 2017

13th Annual Consultant Clinical Pharmacy Seminar

Another successful ConPharm in Hobart

ConPharm ’17 coincided with arguably the city’s premier festival Dark Mofo, which celebrated the dark through large-scale public art, food, film, music, light and noise. Conference attendees enjoyed the opportunity to experience the vast array of festival attractions on offer.

The AACP welcomed over 250 attendees which returned to the Hotel Grand Chancellor, venue for the first ConPharm held in Hobart in 2010. It was opened by AACP Board Chair Joe O’Malley, who in his opening remarks paid tribute to his late mother- in- law Judy Liauw, AACP Board Chair who opened the event in 2010. It was the final conference she attended.

Since ConPharm was first held in 2005, the event has established itself as one of the premier events on the CPD calendar for accredited pharmacists and for those with an interest in this area of practice.

The AACP welcomed back those who have attended and supported the event since its inception. We were also delighted to welcome close to sixty who attended the event for the first time.

This year saw a broad range of presentations delivered by a group of regular event presenters from interstate and a several local speakers who contributed their expertise. During the event Dr Natalie Soulsby was announced as the recipient of the 2017 AACP MIMS Consultant Pharmacist of the Year award.

‘It was a fantastic conference and so well organised-thank you’

‘This is the best overall conference for accredited pharmacists in my opinion. Thanks a million.’

‘Very practical information useful in pharmacy practice this year’

‘Keep up the good work’

‘Fantastic organisation’

 

DAY 1 Friday 16 June 2017
Jo Root

Pharmacists as Integral Part of the Primary Health Care Team – A Consumer Perspective

  1. Discuss the reasons why Primary Health Care matters
  2. Explain the need for integrated care
  3. Describe what consumers think about the role of pharmacists in primary care
  4. Examine additional roles for pharmacists in the primary health care space
Dr Richard Hillock

Evidence-Based Management of Stable Ischaemic Heart Disease: Challenges and controversies

  1. Define and identify the common causes of stable coronary artery disease
  2. Explain the indications and rationale for those medications used in the management of stable coronary artery disease in reference to international published guidelines.
  3. Explain the indications for, and types of, revascularization in the management of SCAD
  4. Identify the limitations of current knowledge in particular related to patient populations underrepresented in large trials
Angus Thompson

Rational Antibiotic Prescribing in the Community

  1. Describe areas of current practice that may contribute to sub-optimal antibiotic use
  2. Discuss opportunities for accredited pharmacists to influence antibiotic use
Dr David Dunbabin

Pleasures and pitfalls of deprescribing and the importance of shared decision making

  1. Recognise what deprescribing involves, and how and why to do it
  2. Identify frailty and how it might affect medical and pharmaceutical decision-making
  3. Discuss the barriers to deprescribing and how they may be overcome
Dr Peter Tenni

Deprescribing: Getting the Patient on Board

  1. Recognise that there is evidence that patient involvement improves the success of deprescribing
  2. Recognise some strategies for deprescribing of benzodiazepines and opioids
Associate Professor Luke Bereznicki

Preventing ADR-related Hospitalisation in the Elderly

  1. Discuss the prevalence of ADR-related hospitalisation in the elderly
  2. Describe the different methods of ADR detection used in the literature
DAY 2 Saturday 17 June 2017
Dr Geraldine Moses

Drug–drug interactions with new Hepatitis C medicines

  1. Explain that managing the drug-drug interactions is key part successful hepatitis C treatment
  2. Describe which CYP enzymes and drug transporters are affected by each direct-acting antivirals (DAAs)
  3. Discuss the management of the common DAA interactions such as those with PPI’s and statins
Professor Jeff Hughes

What is Making Me Fat? Drugs or bugs?

  1. Recognise the causes of overweight and obesity as listed by the World Health organization (WHO)
  2. Discuss and make an argument for and against the potential role of drugs and gut flora in weight gain, and form an opinion on how best to use the current evidence
Debbie Rigby

Diabetic peripheral neuropathy

  1. Identify signs and symptoms of diabetic peripheral neuropathy
  2. Compare effectiveness of medicines for diabetic peripheral neuropathy
  3. Assess risk/benefit of available treatments
Chris Walpole

It’s time for e-health – experiences from a rural GP/Pharmacist collaboration

  1. Describe how ACRRM’s e-health learning tool can be used for GP practices to assist in embedding e-health into their workflows to improve health outcomes, the care experience and reduce health expenditure
  2. Discuss the opportunities for Accredited Pharmacists to be leaders on medication management within a GP practice ensuring that HMRs/RMMRs are uploaded into My Health Record and communicating the benefits of this process
  3. Recognise that accessing My Health Record for the Accredited Pharmacist increases the efficiency and improves the quality of medication management reporting
Dr Brett MacFarlane

Skin care in the older person

  1. Describe the changes that occur in the skin as we age
  2. Describe some of the common skin conditions that affect older people
Dr Jenny Gowan

Seizures in the older person

  1. Discuss the common causes of seizures in older persons
  2. Describe the treatments for newly diagnosed epilepsy in an older person
  3. Identify those drugs which may increase the risk of seizures in older persons
Dr Andrew Stafford

Dementia Update 2017

  1. Describe the amyloid hypothesis in the development of dementia
  2. Explain recent developments in dementia risk factor management
  3. Discuss recent evidence involving the medication management of dementia symptoms
Dr Juanita Westbury

Final outcomes of the RedUSe expansion

  1. Define ‘psycholeptic’ drug
  2. Discuss the strategies and effect of interdisciplinary practice underlying the implementation of the RedUSe project
  3. Explain the overall impact of the RedUSe project in participant RACFs
Dr Lyn Goldberg

Dementia, Oral Health, Dysphagia and Medications

  1. Describe the relationship between oral health and general health and wellbeing
  2. Recognise the vulnerability of adults with dementia to developing aspiration pneumonia and how this can be prevented
  3. Discuss the role of pharmacists in maintaining the oral and general health of adults with dementia
Professor Bastian Seidel and Andrew Ridge

GPs and Pharmacists working together – The Medical Home

  1. Describe current funding arrangements for pharmacists working in GP practices
  2. Discuss important aspects of integration of pharmacists into GP practices
  3. Recognise activities which can be conducted by pharmacists working in GP practices
  4. Describe important roles for GP practice pharmacists
  5. Identify registration requirements for pharmacists working in the GP practice setting
DAY 3 Sunday 19 June 2017
Professor Mark Nelson

The new ‘hypertension’ guidelines – management of high blood pressure (rather than hypertension)

  1. Define ‘absolute risk of a cardiovascular disease (CVD) event’
  2. Describe factors around primary and secondary prevention of CVD and absolute risk
  3. Discuss important factors to remember when taking blood pressure measurements
  4. Discuss important population characteristics of CVD risk
Dr Jenny Gowan

Improving drug safety in patients with Heart Failure: Drugs that may cause or exacerbate Heart Failure

  1. Discuss the common causes of heart failure
  2. Identify the medications which can cause or worsen existing heart failure
  3. Describe the causes of heart failure exacerbations
Dr Chris Freeman

Warfarin Management and the Accredited Pharmacist

  1. Recognise that warfarin is still a widely prescribed anticoagulant
  2. Discuss adherence rates to the new direct oral anticoagulants
  3. Describe the available tools that can be used by accredited pharmacists when reviewing warfarin therapy
Dr Nathan Dwyer

Are Statins for Everyone?

  1. Discuss relative and absolute risk reduction associated with statin use in the primary and secondary prevention of cardiovascular disease
  2. Describe the potential side effects of statins
  3. Identify the statins and their doses which are deemed ‘high intensity’
  4. Describe the potential benefits of statins in patients with low absolute cardiovascular risk
  5. Identify those who may not benefit from statin therapy
Angus Thompson

Dual Oral Antiplatelet Therapy (DAPT) – Lessons from recent trials

  1. Outline the clinical indications for use of DAPT
  2. Discuss current Australian recommendations for use of DAPT following ACS
  3. Describe the contraindications specific to the newer antiplatelet agents
Debbie Rigby

Management of difficult to treat severe asthma – what’s the evidence?

  1. Define severe asthma and describe management strategies
  2. Discuss the role of monoclonal antibodies in the management of severe asthma
  3. Outline which patient groups are best suited to the use of these agents
Zain Elgebaly and Robert DiSipio (NPS MedicineWise)

COPD – lessons learned

  1. Identify barriers to spirometry in the diagnosis of COPD
  2. Outline the stepwise approach to medicines management in COPD, based on COPD-X guidelines
  3. Discuss strategies to assist with the assessment and demonstration of inhaler technique to help patients use inhalers effectively
Professor Jeff Hughes

Photosensitivity Reactions: Causes and Management

  1. Describe the different forms of photosensitivity reactions and differentiate between phototoxic and photoallergic reaction
  2. Outline general advice on how common photosensitivity reactions should be managed
  3. Recognise that some foods may be implicated in the development of phytophotodermatitis
Clinical Controversies and Practice Pointers
Dr Geraldine Moses

Antibiotics prophylaxis for dental procedures – who needs ‘em?

  1. Recognise those patients are appropriate candidates for antibiotic prophylaxis prior to dental procedures, and those who are not
  2. Discuss that professionals and consumers should resist the need for antibiotic prophylaxis if it is not indicated
  3. Provide direction on the best time to take antibiotic prophylaxis when appropriate
Dr Andrew Stafford

Statins and influenza

  1. Discuss the relationship between statins and response to the influenza vaccine
  2. Describe the evidence relating to statins and increased pneumonia risk
Debbie Rigby

Calcium supplements and CVD: has the controversy been resolved?

  1. Describe the dosage range of calcium for which a recent meta-analysis demonstrated an increased risk of myocardial infarction
  2. Discuss best current evidence recommendation for calcium supplementation in relation to CVD
  3. Identify the recommended upper limit for total calcium intake in healthy adults
Professor Jeff Hughes

NSAIDs in the patient with CVD – what are the options?

  1. Describe the risks of using NSAIDs in those with CVD
  2. Discuss the relative risk of the use of different NSAIDs in CVD
  3. Describe recent European data as it relates to NSAID safety in those with heart failure
Main Program – (excluding Antimicrobial Stewardship in Primary Care presentation)

Accreditation Number: A1706ACPP1
This activity has been accredited for 14.25 hours of Group 1 CPD (or 14.25 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 14.25 hours of Group 2 CPD (or 28.5 CPD credits) upon successful completion of relevant assessment activities.

2010 Pharmacist Competencies addressed include: 1.3, 2.1, 2.3, 4.2, 6.1, 6.2, 6.3, 7.1, 7.2, 7.3
2016 Pharmacist Competencies addressed include: 1.5, 2.2, 2.3, 3.1, 3.3, 3.5, 3.6

Main Program presentation titled: Antimicrobial Stewardship in Primary Care

Accreditation Number: A1706ACPP2
This activity has been accredited for 0.75 hours of Group 1 CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan.

2010 Pharmacist Competencies addressed include: 1.3, 2.1, 4.2, 7.1, 7.2, 7.3
2016 Pharmacist Competencies addressed include: 1.5, 2.2, 2.3, 3.1, 3.5